Live
Lonza NewsBRIEF—Lonza and Genetix Biotherapeutics extend deal - The Pharma LetterEndpoints NewsIpsen pulls cancer drug Tazverik from market over safety risksEndpoints NewsWhat Prasad's exit means for the FDA moving forwardAgilentAgilent Technologies to acquire Biocare Medical in $950m deal - Yahoo FinanceBioPharma DiveRoche’s prized breast cancer pill fails closely watched studyFierceBiotechTenacia builds $308M biobucks deal with Rapport to develop epilepsy drug in greater ChinaFierceBiotechFDA greenlights backup anti-choking suction deviceFierceBiotechXenon phase 3 epilepsy readout 'blows away' expectations, stock soarsFierceBiotechBMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3BioPharma DiveUniQure leads genetic medicine biotech rally after news of Prasad’s exitAgilentAgilent to buy Biocare Medical for $950M - MedTech DiveBioPharma DiveIpsen to withdraw cancer drug acquired in buyout due to safety concerns
FierceBiotech Mar 9, 2026

BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3

BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3

Original
Body unavailable. Use the original source.

Directory

59 All